This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Mar;19(3):274-275.

doi: 10.1016/S1470-2045(18)30064-0. Epub 2018 Jan 26.

Immune checkpoint inhibitors: the next step for thymic carcinomas

Affiliations

Affiliation

¹ Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Centre Komagome Hospital, Tokyo 113-8677, Japan. Electronic address: y-okuma@cick.jp.

PMID: 29395865
DOI: 10.1016/S1470-2045(18)30064-0

Comment

Immune checkpoint inhibitors: the next step for thymic carcinomas

Yusuke Okuma. Lancet Oncol. 2018 Mar.

. 2018 Mar;19(3):274-275.

doi: 10.1016/S1470-2045(18)30064-0. Epub 2018 Jan 26.

Author

Affiliation

¹ Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Centre Komagome Hospital, Tokyo 113-8677, Japan. Electronic address: y-okuma@cick.jp.

PMID: 29395865
DOI: 10.1016/S1470-2045(18)30064-0

No abstract available

PubMed Disclaimer

Comment on

Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.
Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, Manning M, Mogg R, Blumenschein WM, Tan MT, Subramaniam DS, Liu SV, Kaplan IM, McCutcheon JN. Giaccone G, et al. Lancet Oncol. 2018 Mar;19(3):347-355. doi: 10.1016/S1470-2045(18)30062-7. Epub 2018 Jan 26. Lancet Oncol. 2018. PMID: 29395863 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions